C-terminal variants in CDC42 drive type I interferon-dependent autoinflammation in NOCARH syndrome reversible by ruxolitinib
Research output: Contribution to journal › Case report › Contributed › peer-review
Contributors
Abstract
C-terminal variants in CDC42 encoding cell division control protein 42 homolog underlie neonatal-onset cytopenia, autoinflammation, rash, and hemophagocytic lymphohistiocytosis (NOCARH). Pyrin inflammasome hyperactivation has been shown to contribute to disease pathophysiology. However, mortality of NOCARH patients remains high despite inflammasome-focused treatments. Here, we demonstrate in four NOCARH patients from three families that cell-intrinsic activation of type I interferon (IFN) is a previously unrecognized driver of autoinflammation in NOCARH. Our data show that aberrant innate immune activation is caused by sensing of cytosolic nucleic acids released from mitochondria, which exhibit disturbances in integrity and dynamics due to CDC42 dysfunction. In one of our patients, treatment with the Janus kinase inhibitor ruxolitinib led to complete remission, indicating that inhibition of type I IFN signaling may have an important role in the management of autoinflammation in patients with NOCARH.
Details
Original language | English |
---|---|
Article number | 109777 |
Journal | Clinical immunology |
Volume | 256 |
Publication status | Published - Nov 2023 |
Peer-reviewed | Yes |
External IDs
ORCID | /0000-0002-8375-8233/work/143958309 |
---|---|
ORCID | /0000-0002-4330-1861/work/143958616 |
Keywords
ASJC Scopus subject areas
Keywords
- Autoinflammation, CDC42, JAK inhibition, NOCARH, Ruxolitinib, Type I interferonopathy